In a statement, the company said, Our new marketing campaign, supported by clinical research and conversations with our patients, aims to start an important, sometimes difficult, conversation focused on de-stigmatizing obesity as a condition and highlighting a new, incredibly effective treatment that may, for the first time, be a real solution for millions of people. The statement continued: We recognize that these are difficult conversations to have and that not everyone will love our marketing. On Friday, a Ro spokesperson said that thinking applies equally to recent ads on social media
Too much Semaglutide can result in low blood sugar (hypoglycemia) or nausea
Understanding these variables helps set realistic expectations and prevents unnecessary frustration
Switching from Wegovy to Mounjaro requires a healthcare provider to adjust the dose carefully for safety and effectiveness
In March 2021, a pivotal clinical trial called STEP 1 was published showing once-weekly injectable semaglutide resulting in an impressive 14.9% average reduction in body weight in individuals with obesity without diabetes mellitus
Key References Burlina S, Dalfra MG, Caprino R, Lapolla A
